- Home
- Companies
- Futura Medical
- Articles
Futura Medical articles
Futura Medical`s novel OTC topical erectile dysfunction treatment MED3000 will be launched across numerous European markets by France`s Cooper Consumer Health.
You may also be interested in...
Futura Medical has announced positive results from a clinical trial looking into MED3000, a topical gel formulation for the treatment of erectile dysfunction (ED).
The results, from the confirmatory phase 3 clinical study, FM71, were announced today (August 31).
MED3000 is a breakthrough, fast-acting gel produced by Futura Medical’s transdermal DermaSys drug delivery technology. It is
Futura Medical (LON: FUM) says that the clinical study for the MED3000 topical gel erectile dysfunction treatment has met its primary and secondary endpoints. They showed an improvement in erectile function and a highly statistic improvement in the onset of action at 10 minutes. There were limited side effects with 4.3% of patient suffering headaches and a further 4.3% nausea, which is much better than rival treatment tadalafil. The next move is subm